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Signal Transducer and Activator of Transcription
3-Mediated CD133 Up-Regulation Contributes to
Promotion of Hepatocellular Carcinoma
Cheolhee Won,1,2* Byung-Hak Kim,1,3* Eun Hee Yi,1 Kyung-Ju Choi,4 Eun-Kyung Kim,5 Jong-Min Jeong,6
Jae-Ho Lee,7 Ja-June Jang,8 Jung-Hwan Yoon,9 Won-Il Jeong,6 In-Chul Park,10 Tae Woo Kim,11 Sun Sik Bae,5
Valentina M. Factor,12 Stephanie Ma,13 Snorri S. Thorgeirsson,12 Yun-Han Lee,4 and Sang-Kyu Ye1,2,14
Enhanced expression of the cancer stem cell (CSC) marker, CD133, is closely associated
with a higher rate of tumor formation and poor prognosis in hepatocellular carcinoma
(HCC) patients. Despite its clinical significance, the molecular mechanism underlying the
deregulation of CD133 during tumor progression remains to be clarified. Here, we report
on a novel mechanism by which interleukin-6/signal transducer and activator of tran-
scription 3 (IL-6/STAT3) signaling up-regulates expression of CD133 and promotes HCC
progression. STAT3 activated by IL-6 rapidly bound to CD133 promoter and increased
protein levels of CD133 in HCC cells. Reversely, in hypoxic conditions, RNA interference
silencing of STAT3 resulted in decrease of CD133 levels, even in the presence of IL-6,
with a concomitant decrease of hypoxia-inducible factor 1 alpha (HIF-1a) expression.
Active STAT3 interacted with nuclear factor kappa B (NF-jB) p65 subunit to positively
regulate the transcription of HIF-1a providing a mechanistic explanation on how those
three oncogenes work together to increase the activity of CD133 in a hypoxic liver micro-
environment. Activation of STAT3 and its consequent induction of HIF-1a and CD133
expression were not observed in Toll-like receptor 4/IL-6 double-knockout mice. Long-
term silencing of CD133 by a lentiviral-based approach inhibited cancer cell-cycle pro-
gression and suppressed in vivo tumorigenicity by down-regulating expression of
cytokinesis-related genes, such as TACC1, ACF7, and CKAP5. We also found that sorafe-
nib and STAT3 inhibitor nifuroxazide inhibit HCC xenograft formation by blocking acti-
vation of STAT3 and expression of CD133 and HIF-1a proteins. Conclusion: IL-6/STAT3
signaling induces expression of CD133 through functional cooperation with NF-jB and
HIF-1a during liver carcinogenesis. Targeting STAT3-mediated CD133 up-regulation may
represent a novel, effective treatment by eradicating the liver tumor microenvironment.
(HEPATOLOGY 2015;62:1160-1173)
H
epatocellular carcinoma (HCC) is the sixth-
most commonly diagnosed and the third-most
lethal neoplasm causing an estimated 700,000
deaths worldwide annually.1 In the United States, the
incidence of HCC has doubled over the past two deca-
des, with only 30%40% of patients eligible for cura-
tive treatments, such as liver transplantation or surgical
resection owing to late diagnosis, underlying liver dis-
ease, and lack of effective treatment options.2 HCC is
closely associated with chronic inflammation caused by
viral hepatitis, alcoholic liver disease, and autoimmune
hepatitis, in which continuous inflammation and hepa-
tocyte regeneration occur.3 These long-term processes
may include accumulation of genetic and/or epigenetic
changes, alteration of liver tumor microenvironment,
and generation of liver cancer stem cells (CSCs).4
Abbreviations: Bcl-2, B-cell lymphoma 2; Bcl-xL, B-cell lymphoma-extra large; ChIP, chromatin immunoprecipitation; CSC, cancer stem cell; DEN, diethylni-
trosamine; DMSO, dimethyl sulfoxide; FACS, fluorescence-activated cell sorting; FCM, flow cytometry; HCC, hepatocellular carcinoma; HDAC, histone deacetylase;
HIF-1a, hypoxia-inducible factor 1 alpha; IgG, immunoglobulin G; IHC, immunohistochemistry; IL-6, interleukin-6; JAK, janus kinase; KAIST, Korea Advanced
Institute of Science and Technology; KO, knockout; Mcl-1, myeloid cell leukemia 1; MKI, multiple tyrosine kinase inhibitor; mRNA, messenger RNA; NF-jB,
nuclear factor kappa B; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; RNAi, RNA interference; SC, subcutaneously; shRNA, short hairpin
RNA; siRNA, small interfering RNA; shRNA, short hairpin RNA; STAT3, signal transducer and activator of transcription 3; TLR-4, Toll-like receptor 4; TRAIL,
tumor necrosis factor–related apoptosis-inducing ligand; VEGF, vascular endothelial growth factor; WT, wild type.
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Recently, growing evidences support the novel notion that
tumor initiation can be driven by a CSC subset that is
responsible for tumor persistence and relapse, metastasis,
chemoresistance, and radioresistance. CD133 antigen, also
known as prominin 1, has been identified as a putative CSC
marker in various cancer types, including HCC.5 CD1331
cells possess greater colony-forming efficiency, higher prolif-
eration rate, and higher incidence of tumorigenesis. Clini-
cally, HCC patients with increased CD133 levels have
shorter overall survival and higher recurrence rates than
patients with low CD133 expression.6 Despite the immense
clinical significance, molecular mechanisms underlying
enhanced expression of CD133 remain to be defined.
Aberrant activation of signal transducer and activator
of transcription 3 (STAT3) is frequently associated with
various human malignancies, including liver, hemato-
logical, breast, head and neck, and prostate cancers.7
Many compelling evidences support that STAT3 is criti-
cal in inflammation-associated tumorigenesis by regulat-
ing numerous oncogenic and inflammatory genes.8
Interleukin-6 (IL-6), a potent STAT3 activator, is highly
released in response to hepatitis viral infection and sys-
temic inflammation in the liver.9 The IL-6/STAT3-sig-
naling pathway has been previously reported to be
involved in liver inflammation/regeneration.10 It main-
tains liver CSC population by interacting with the trans-
forming growth factor beta–signaling pathway.11 More
recently, it has been found that CD241 liver CSCs, a
subset of cells that shares a high overlapping expression
as CD1331 liver CSCs, drive tumor initiation through
STAT3-mediated NANOG regulation.12
The hypoxic microenvironment of a developing tumor
has been shown to be correlated to regulation of immune
response and inflammation promotion.13 In malignant
tumors, macrophages rapidly up-regulate expression of
IL-6 under hypoxic conditions by altering expression of a
wide array of genes.14 Expression of hypoxia-responsible
genes is shown to be almost doubled when stimulated
with IL-6 in HCC cells.15 Of those, hypoxia inducible fac-
tor 1 alpha (HIF-1a) is a key hypoxia-regulatory protein
that not only contributes to restoration of oxygen homeo-
stasis by promoting glycolysis, erythropoiesis, and angio-
genesis, but also plays an important role in acquiring
resistance against chemotherapeutic agents.16 Recent stud-
ies have shown that autocrine IL-6 induces a loss of meth-
ylation at the CD133 proximal promoter region in breast
cancer cells,17 and that activated HIF-1a enhances self-
renewal activity of CD1331 cells and inhibits induction
of CSC differentiation.18
Putting these evidences together, we hypothesized
that CD133 might be an inducible gene in HCC pro-
gression, rather than just a CSC marker, which is consis-
tently expressed in a particular subset of cells in the liver
tumor microenvironment. Our results provided in vitro
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and in vivo evidences that IL-6-mediated activation of
STAT3 induces expression of CD133 through transcrip-
tional activation in liver carcinogenesis. This up-regulation
is accompanied with functional activation of the key down-
stream players, nuclear factor-kappa B (NF-jB) and HIF-
1a. Treatment of sorafenib and STAT3 inhibitor nifuroxa-
zide effectively suppressed HCC xenograft formation by
blocking activation and expression of STAT3, CD133, and
HIF-1a proteins. Our findings provide not only a novel
mechanism of IL-6/STAT3 signaling-mediated CD133
up-regulation to drive HCC, but also an effective molecu-
lar pathway that can be targeted with the hope of eradicat-
ing the liver tumor microenvironment.
Materials and Methods
Human HCC Tissue Collection. Twenty pairs of
liver tumor and adjacent noncancerous tissue specimens were
collected from the Department of Pathology, Seoul National
University College of Medicine (Seoul, Korea), with institu-
tional review board approval. All patients participating in this
study gave their informed consent before surgery.
Cell Lines. Human HCC cell lines, Hep3B, Huh7,
PLC/PRF/5, SNU-398, SNU-423, SNU-449, SNU-
761, and SNU-878, and a human hepatoblastoma cell
line, HepG2, were purchased from ATCC (Manassas,
VA) or Korean Cell Line Bank (Seoul, Korea). Normal
liver epithelial cell line Chang was purchased from CLS
Cell Line Service (Eppelheim, Germany).
Cloning Human CD133 Promoter and STAT3-
Specific Short Hairpin RNA Construction. A 2.4-
kilobase region of human CD133 promoter was ampli-
fied by polymerase chain reaction (PCR) from human
U2OS genomic DNA using primers. PCR-amplified
fragments were cloned into KpnI and XhoI sites of
pGL3-basic luciferase vector (Promega, Madison, WI).
STAT3-specific short hairpin RNA (shRNA) was
designed using BLOCK-iTTMRNAi Designer (Invitro-
gen, Carlsbad, CA) (Supporting Table 1) and annealed
both strands to generate double-stranded oligos with 4-
nucleotide overhangs. Double-stranded oligos were then
directly inserted into BLOCK-iTTMpENTRTM/H1/TO
RNA interference (RNAi) vector (Invitrogen).
shRNA Preparation and Plasmid Construction.
pLKO plasmid (OriGene, Rockvile, MD) was used for
lentiviral DNA vector-based shRNA construction. Based
on complementary DNA sequence of CD133 (Gen-
Bank accession no.: NM_001145847) and STAT3
(GenBank accession no.: NM_003150), an shRNA
designing tool was provided freely by Invitrogen at its
website (www.invitrogen.com/rnai). We synthesized
DNA templates encoding one CD133-specific shRNA
and one STAT3-specific shRNA. The core sequences of
oligonucleotides encoding CD133 and STAT3 shRNA
were 5’-CATTGGCATCTTCTATGG-3’ and 5’-
GCGTCCAGT TCACTACTAAAG-3’, respectively.
In Vivo Tumorigenicity Experiments. Viable
Huh7 cells were injected subcutaneously (SC) into the
dorsal flank of Balb/c nude mice (1 3 106 cells/mouse).
Tumor-bearing mice were then randomly assigned to three
groups when tumor sizes were reached to 10 mm in diam-
eter. Each group (n5 6) was treated with vehicle (1%
dimethyl sulfoxide [DMSO] diluted into phosphate-
buffered saline [PBS]), 30 mg/kg of sorafenib, or 60 mg/
kg of nifuroxazide with a 2-day interval during 2 weeks.
All surgical and experimental procedures were approved
by the institutional animal care and use committee at the
Seoul National University College of Medicine (Seoul,
Korea). Tumors were measured by a caliper ruler with a 2-
day interval, and tumor volumes were calculated using a
3 b2/2 (where a is the width at the widest point of the
tumor and b is the width perpendicular to a).
DEN-Induced Liver Cancer Model. Male
C57BL/6J wild-type (WT), IL-6 knockout (KO; IL-62/
2), and Toll-like receptor 4 (TLR-4) knockout (TLR-
42/2) mice were purchased from The Jackson Labora-
tory (Bar Harbor, ME). To obtain IL-6–/–/TLR-4–/–
double KO, IL-62/2 mice were crossed with TLR-42/2
mice. Mice were maintained in a specific pathogen-free
facility at the Korea Advanced Institute of Science and
Technology (KAIST; Daejeon, South Korea). All ani-
mals received humane care according to the criteria out-
lined in the Guide for the Care and Use of Laboratory
Animals published by the National Institutes of Health.
The animal protocol was approved by the institutional
animal care and use committee of KAIST. To induce
HCC, 2-week-old male mice received an intraperitoneal
injection of diethylnitrosamine (DEN; 20 mg/kg;
Sigma-Aldrich, St. Louis, MO) and mice were sacrificed
at 10 months after DEN treatment.
Microarray Analysis. Total RNAwas extracted from
Huh7 cells transduced with either lentiviral vector or
shCD133 using TRIzol reagent, in vitro transcribed, and
hybridized on Illumina Human HT-12 v4 Expression
BeadChip (Illumina, San Diego, CA). All microarray data
were submitted to the Gene Expression Omnibus database
with the accession number GSE60194. Statistical analysis
was performed using R and BioConductor software
(http://www.bioconductor.org/). All data were normalized
with robust spline normalization method after variance-
stabilizing transformation provided by the LUMI package.
Statistical Analysis. All data were statistically ana-
lyzed using Microsoft Excel 2013 software (Microsoft,
Redmond, WA) or Sigma Plot 12. Tumor volumes in
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vehicle-, sorafenib-, and nifuroxazide-treated groups
were compared by analysis of variance followed by Dun-
can’s multiple range test. Differences were considered
statistically significant at the P< 0.05 level. All statistical
tests were two-sided.
Results
Enhanced Levels of Active STAT3, HIF-1a, and
CD133 in Human HCC Clinical Specimen and
DEN-Induced HCC Mouse Model. HCC is mainly
caused by either hepatitis B– or C–type virus, both of
which are accompanied with chronic inflammation and
hypoxia.19,20 Therefore, as a first step, we examined lev-
els of active STAT3 (pY705-STAT3), HIF-1a, CD133,
and IL-6 in fresh tumor tissues and blood samples of
HCC patients by immunohistochemistry (IHC) and
enzyme-linked immunosorbent assay analyses. IHC
demonstrated that levels of active STAT3, HIF-1a, and
CD133 were significantly elevated in HCC, tissues
when compared to adjacent noncancerous tissues (Fig.
1A). In addition, serum levels of proinflammatory cyto-
kine IL-6 were consistently higher in HCC patients
than in control subjects (Fig. 1B). Importantly, active
STAT3 was colocalized with CD133 as well as HIF-1a
(Supporting Fig. 1), indicating that their functions are
positively correlated in tumorigenesis. Consistent with
the observation in human HCC tissues, levels of active
Fig. 1. Levels of active STAT3, HIF-1a, CD133, and IL-6 were elevated in HCC progression. (A) H&E staining and IHC revealed activation of
STAT3 and enhanced expression of HIF-1a and CD133 in human HCC tissues, when compared to adjacent noncancerous tissues. Scale
bar5 100 lm. (B) Plasma IL-6 levels were determined in cohorts of healthy adults (n5 10) and HCC patients (n5 20). **P< 0.005. (C) Con-
firmation of activation of STAT3 and enhanced expression of HIF-1a and CD133 in the DEN-induced HCC model. Scale bar5 50 lm. (D and E)
Active endogenous STAT3 and IL-6Ra (D) and CD133 and gp130 (E) levels were determined by western blotting or reverse-trancriptase PCR
analysis in human HCC cell lines. GAPDH and b-actin were used as loading controls. Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehy-
drogenase; H&E, hematoxylin and eosin.
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STAT3, HIF-1a, and CD133 were significantly
increased in DEN-induced liver tumors, when com-
pared to normal liver in a control C57BL/6J WTmouse
(Fig. 1C). Before addressing the hypothesis of this study,
we checked in advance the expression status of active
STAT3 and CD133 as well as IL-6 receptors, such as
IL-6Ra and gp130, in normal liver Chang and various
HCC cell lines (Hep3B, HepG2, Huh7, PLC/PRF/5,
SNU-398, SNU-423, SNU-449, SNU-761, and SNU-
878). Active STAT3 was detected in almost all cell lines,
but not in Chang and Hep3B cells (Fig. 1D). CD133
messenger RNA (mRNA) was not detected in all cell
lines, but expressed, albeit at a slightly different degree,
in a subset of HCC cell lines, such as Hep3B, HepG2,
Huh7, PLC/PRF/5, and SNU-878 (Fig. 1E). Detection
of CD133 protein levels by fluorescence-activated cell
sorting (FACS) analysis confirmed this phenomenon
(Supporting Fig. 2). Overall, levels of active STAT3
were not coincided with the endogenous expression of
CD133. This might be owing to the different genetic
characterization of each cell line. However, IL-6Ra and
gp130 were ubiquitously expressed in all HCC cell lines
tested (Fig. 1D,E). Thus, we used this different status of
CD133 to experimentally prove the functional role of
IL-6/STAT3 signaling to induce CD133 expression in
HCC progression.
IL-6 and STAT3 Promote CD133 Transcription.
In light of increased expression of liver tumor microen-
vironmental factors in HCC, we then investigated
whether elevated levels of IL-6 could affect CD133 tran-
scriptional activity. In serum-free culture conditions,
addition of IL-6 promoted transcriptional activity of
CD133 by around 2-fold in Huh7 cells (Fig. 2A) and
subsequently increased the portion of CD1331 cell pop-
ulation by approximately 2.4-fold (Fig. 2B). Next, we
asked how exogenous ligand IL-6 could activate the
function of CD133. Both janus kinase (JAK) and
STAT3 have previously been shown to be critical in
mediating IL-6 receptor-mediated signaling cascades to
transcribe expression of a variety of downstream target
genes, such as c-Myc and Mcl-1, which have been
shown to be involved in cancer cell proliferation or inhi-
bition of apoptosis.21 Thus, we performed various
experimental approaches to confirm the involvement of
STAT3 in activation of CD133 transcription. Addition
of IL-6 induced expression of CD133 both in mRNA
and protein levels through activation of STAT3 (Fig.
2C). However, functional inactivation of STAT3 by
pan-JAK inhibitor AG-490 abolished the induction of
CD133 expression and decreased the levels of active
STAT3 (Fig. 2C). The reverse inhibition of CD133
expression by AG-490 was similarly observed in other
HCC cell lines of PLC/PRF/5, SNU-449, Hep3B, and
SNU-398 (Fig. 2D and Supporting Fig. 3A). Interest-
ingly, IL-6 stimulation was able to induce expression of
CD133, even in the SNU-449 and SNU-398 cell lines
in which endogenous CD133 mRNA levels were very
low or not detected by PCR (Fig. 1E), indicating that
CD133 is an IL-6-inducible gene. Furthermore, treat-
ment of AG-490 decreased activities of JAK1, JAK2,
and STAT3. Consequently, expression of CD133 was
decreased both in Huh7 and PLC/PRF/5 cells, which
highly express CD133 without IL-6 stimulation (Fig.
2E), implying that endogenous expression of CD133 is
maintained by IL-6 signaling. STAT3 activated by IL-6
was found to be translocated into the nucleus (Fig. 2F),
and then increased the levels of acetylated histone H3
by directly binding to CD133 promoter (Supporting
Fig. 3B). This phenomenon was owing to corecruitment
of acetyl transferase p300 and active STAT3 to the
CD133 promoter, mainly leading to acetylation of his-
tone H3 at lysine 9 and histone H4 at lysine 12 residues,
whereas epigenetic regulators for histone deacetylation,
such as histone deacetylase (HDAC)1, HDAC3, and
MeCP2, were gradually dissociated from the CD133
promoter upon cytokine stimulation (Supporting Fig.
3C). Targeting of HDACs (HDAC1, HDAC2, and
HDAC3) with pan-HDAC inhibitor SAHA blocked
induction of CD133, even in the presence of IL-6 (Sup-
porting Fig. 3D). These results suggest that histone
modification functionally involves IL-6/STAT3-medi-
ated transcriptional activation of CD133. To further
confirm that IL-6 induces CD133 expression, CD1331
CSC population was sorted out from the CD1332 pop-
ulation of Huh7 cells by FACS using allophycocyanin-
conjugated CD133 antibody. Both types of populations
were incubated with IL-6 and then induction of CD133
expression and sphere forming capacity was observed.
As a result, IL-6 stimulation increased expression of
CD133 and stemness-related genes, such as Nanog,
Sox-2, and Oct-4, both in CD1331 and CD1332 cells
(Supporting Fig. 4A). These molecular changes led to
the phenotypic changes in terms of increase in size of
CD1331 cell population and sphere-forming capacity
(Supporting Fig. 4B, 4C), providing that CD133 up-
regulation reflects increase in cancer stemness. Notice-
ably, the extent of increase in CD133 expression was
much more in CD1332 cancer cells than in CD1331
cancer stem cells, when compared to each control not
stimulated with IL-6 (e.g., 8.4%-46.7% vs. 11.8%-
20.0%). The increase of CD133 expression was accom-
panied with up-regulation of cell-cycle regulators, such
as cyclin A1 and cyclin D1, but levels of p21 were not
changed (Supporting Fig. 4D). Direct inhibition of
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STAT3 expression by STAT3-specific small interfering
RNA (siRNA) showed a similar effect with AG-490,
abolishing up-regulation of CD133 both in Huh7 and
PLC/PRF/5 cells (Fig. 3A,B). Recently, it has been dem-
onstrated that TLR-4 induces downstream IL-6 gene
expression in tumorigenesis.22 Thus, we next observed
the expression status of the three important regulators in
the DEN-induced HCC mouse model with TLR-4/IL-
6 double KO. As a result, blockade of IL-6 expression
neither activated the function of STAT3 nor induced
expressions of HIF-1a and CD133 (Fig. 3C). Taken
together, these data strongly suggest that IL-6-mediated
STAT3 activation plays a pivotal role in the induction of
CD133 expression in HCC progression.
IL-6/STAT3 Signaling Increases CD133 Expres-
sion by HIF-1a in Hypoxia. Recent studies reported
that hypoxia not only activates HIF-1a to strengthen
self-renewal activity and maintain the undifferentiated
status of CD133-expressing cells,18 but also provokes
endogenous c-Src/STAT3-signaling cascade.23 There-
fore, we examined whether hypoxia could trigger
STAT3-mediated CD133 up-regulation. In a hypoxic
condition, transient transfection of the active form of c-
Src (c-SrcY527F) significantly increased STAT3 activity
and CD133 expression in Huh7 cells with a concomi-
tant increase of HIF-1a levels, and the effects were abol-
ished by expressing the inactive form of c-Src (c-
SrcY416F; Fig. 4A). This negative effect was further
Fig. 2. IL-6 induces CD133 expression through activation of STAT3 signaling. (A) Huh7 cells were transfected with CD133-promoter-Luc and
pRL-TK constructs and incubated for 16 hours with IL-6 (20 ng/mL). Luciferase activities were normalized to Renilla activities (mean6 standard
deviation). *P< 0.05. (B) Huh7 cells cultured in serum-free media were incubated with IL-6 (20 ng/mL) for 24 hours. CD133 expression was
quantified by FCM. (C) Huh7 cells were pretreated with AG-490 (100 lM) for 2 hours and then incubated with IL-6 (20 ng/mL) for 12 hours in
serum-free conditions. CD133 and active STAT3 levels were determined by western blotting or reverse-trancriptase PCR (RT-PCR) analysis. (D)
PLC/PRF/5 and SNU-449 cells pretreated with AG-490 (100 lM) for 1 hour were incubated with IL-6 (20 ng/mL) for 12 hours in a serum-free
condition. CD133 levels were determined by RT-PCR. (E) Huh7 and PLC/PRF/5 cells were pretreated with AG-490 (100 lM) for 2 hours and
then incubated for 12 hours. CD133, active JAK1, JAK2, and STAT3 levels were determined by western blotting or RT-PCR analysis. (F) Huh7 cells
were incubated with IL-6 (20 ng/mL) for 30 minutes in a serum-free condition. Proteins were extracted from both cytosol and nuclei in order to
examine localization of STAT3. Lamin B and GAPDH were used as nucleic and cytosolic markers, respectively. Abbreviations: 7-AAD, 7-aminoacti-
nomycin D; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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validated by inhibiting expression of STAT3 by shRNA
(Fig. 4B). Sorafenib, a multityrosine kinase inhibitor, is
the first approved targeted therapeutic reagent for HCC.
Mechanistically, it has been recently reported that sora-
fenib not only overcomes tumor necrosis factor–related
apoptosis-inducing ligand (TRAIL) resistance of HCC
cells through inhibition of STAT3 activity,24 but also
suppresses angiogenesis by blocking synthesis of HIF-1a
in HCC.25 Thus, we tested whether sorafenib could
inhibit STAT3-mediated CD133 up-regulation upon
hypoxia. As expected, treatment of sorafenib to hypoxic
Huh7 cells showed a similar effect with shRNA silencing
of STAT3, down-regulating expression of CD133 with
a concomitant decrease in levels of STAT3 and HIF-1a
(Fig. 4B). Phenotypically, sorafenib treatment signifi-
cantly reduced the size of the IL-6-induced CD1331
Huh7 cell population (Fig. 4C). These data indicate
that STAT3 up-regulates CD133 expression through
activation of HIF-1a signaling upon hypoxic stimula-
tion. Our next question was whether endogenous HIF-
1a protein is essential for facilitation of CD133 up-
regulation. Substantially, siRNA silencing of HIF-1a
significantly decreased levels of CD133 in hypoxic con-
ditions (Fig. 4D). Next, we tested whether the combina-
tion of hypoxia with IL-6 stimulation could
synergistically affect STAT3-mediated CD133 up-
regulation. Surprisingly, the combinatory stimuli effect
was almost doubled in terms of the increase of both
Fig. 3. IL-6 induces CD133 expression in a STAT3-dependent manner. Huh7 (A) and PLC/PRF/5 cells (B) were transfected with CD133-pro-
moter-Luc and pRL-TK constructs with or without scrambled or STAT3 siRNA. The cells were incubated with IL-6 (20 ng/mL) in the presence or
absence of either vehicle or AG-490 (100 lM) for 24 hours. Luciferase activities were measured and normalized to Renilla activities (mean-
6 standard deviationSD), and CD133 and active STAT3 levels were determined by western blot or reverse-trancriptase PCR analysis. *P< 0.05
versus vehicle-treated group; **P< 0.05 versus IL-6-induced or scramble siRNA-transfected group (n5 6). GAPDH and b-actin were used as
loading controls. (C) H&E staining and IHC confirmed that blockade of IL-6 expression did not induce activation of STAT3 and expression of HIF-
1a and CD133 in TLR-4/IL-6 double-KO mice. Scale bar5 50 lm. Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; H&E,
hematoxylin and eosin.
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STAT3 activity and CD133 levels, when compared with
single stimulus, in Huh7 cells (Fig. 4E). The synergistic
effect was reproduced in four additional HCC cell lines
(PLC/PRF/5, SNU-398, Hep3B, and SNU-449),
regardless of the difference in endogenous levels of
CD133 expression (Supporting Fig. 5). Sorafenib treat-
ment completely abolished STAT3-mediated CD133
up-regulation. These results strongly imply that proin-
flammatory signaling can boost HCC development
under the hypoxic liver tumor microenvironment
through STAT3-mediated CD133 up-regulation.
Active STAT3 Directly Interacts With NF-jB p65
and Recruits It to HIF-1a Promoter in Hypoxia.
Hypoxia enhances activity of transcription factor NF-
jB, which is required for mRNA expression of HIF-1a,
by inhibiting prolyl hydroxylases that negatively regulate
I kappa B kinase beta catalytic activity.26 Persistently
activated STAT3 directly binds to released nuclear NF-
jB and maintains its activity by blocking NF-jB/I
kappa B complex from shuttling out of the nucleus.27
Thus, we were determined to investigate whether the
functional activity of NF-jB could correlate to STAT3/
HIF-1a cooperation to exert CD133 up-regulation in
the hypoxic tumor microenvironment. We have
observed that both active STAT3 and NF-jB are trans-
located into the nucleus upon hypoxia (Fig. 5A) and
active STAT3 binds to endogenous NF-jB p65 in HCC
cells tested (Fig. 5B). To validate a predictive binding of
STAT3/NF-jB p65 dimer to the HIF-1a promoter
region, we performed a chromatin immunoprecipitation
(ChIP) assay by using the antibodies to high-quality
ChIP-grade active forms of STAT3, NF-jB p65,
Fig. 4. STAT3-dependent HIF-1a levels regulate CD133 expression in hypoxia. (A) Huh7 cells were transfected with either control vector, active
c-Src (c-SrcY527F), or inactive c-Src (c-SrcY416F), and cells were incubated under hypoxic conditions for 40 hours. Western blotting analysis was
then performed with the indicated antibodies. (B) Huh7 cells were transfected with either scrambled or STAT3 shRNA and incubated for 40 hours
in the presence or absence of sorafenib (0.5 lM) under hypoxic conditions. Western blotting or reverse-trancriptase PCR analysis was then per-
formed. (C) Huh7 cells were incubated with IL-6 (20 ng/mL) for 24 hours in the presence or absence of sorafenib and the CD133 population
was detected by FCM. (D) Huh7 cells were transfected with either scrambled or HIF-1a siRNA and then incubated under hypoxic conditions for
40 hours. Proteins were analyzed by western blotting analysis. (E) Huh7 cells were pretreated with sorafenib (0.5 lM) for 1 hour and then incu-
bated with IL-6 (20 ng/mL) for 24 hours under hypoxic conditions. Western blotting analysis was performed. GAPDH was used as a loading con-
trol. Abbreviation: GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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acetylated histone H3, and rabbit immunoglobulin G
(IgG) control. Importantly, high enrichment of active
STAT3/NF-jB p65 to the HIF-1a promoter was
detected in hypoxia-stimulated Huh7 cells (Fig. 5C).
Sorafenib treatment reverted hypoxia-induced STAT3
activation and inhibited binding of STAT3/NF-jB p65
dimer to the HIF-1a promoter. These data clearly sug-
gest that active STAT3 directly interacts with NF-jB
p65 and recruits it to the HIF-1a promoter under
hypoxic conditions. This may represent a novel molecu-
lar mechanism by which STAT3, NF-jB, and HIF-1a
work together to induce expression of the CSC marker,
CD133, during HCC development.
Functional Loss of CD133 Reduces Tumorigenic
Potency In Vitro and In Vivo. To address the bio-
logical functions of CD133 in HCC tumor formation,
Huh7 and PLC/PRF/5 were transfected with lenti-
shRNA molecules and then observed for growth inhibi-
tion. Target gene knockdown was specific because trans-
fection with a negative control shRNA did not affect
CD133 transcription (Fig. 6A). Targeting CD133
caused a significant reduction in growth rate of HCC
cells in 72 hours, when compared to control shRNA
treatment (Fig. 6B). shRNA silencing of CD133 gene
expression did not affect the growth of SNU-449 cells
in which endogenous CD133 level is very low (Support-
ing Fig. 6). Instead, the growth rate of cells was remark-
ably increased when CD133 was up-regulated by IL-6
stimulation, compared to control shRNA transduction
(Supporting Fig. 6). This phenomenon was reversed by
sorafenib treatment, indicating that suppression of
CD133 expression is one of the molecular mechanisms
underlying the tumor growth-inhibitory effect caused by
sorafenib treatment. We next investigated whether
shRNA silencing of CD133 could suppress liver tumor
growth in vivo. To accomplish this, 1 3 106 cells with
Huh7-lenti-vehicle or Huh7-lenti-shCD133 were SC
injected into immunodeficient mice and then observed
Fig. 5. Active STAT3 directly interacts with NF-jB p65 and recruits it to the HIF-1a promoter region in hypoxia. (A) HCC cells were incubated
under hypoxic conditions for 6 hours. Proteins were extracted from both cytosol and nuclei fractions in order to examine localization of HIF-1a,
active STAT3, and NF-jB p65. Lamin B and GAPDH were used as nucleic and cytosolic markers, respectively. (B) Huh7 and PLC/PRF/5 cells
were transfected with either control vector or wt-STAT3 for 24 hours and further exposed to hypoxia for 6 hours. Cell lysates were immunoprecipi-
tated with anti-pY705-STAT3 antibody and then incubated with the indicated antibodies. (C) Soluble chromatin was prepared from Huh7 cells and
then immunoprecipitated with the indicated antibodies. DNA extracts were amplified using pairs of primers that cover putative consensus motif
of the HIF-1a promoter. Abbreviation: GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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for tumorigenicity. Tumors grew very rapidly in control
mice that received Huh7-lenti-vehicle cells, whereas
shRNA silencing significantly inhibited xenograft for-
mation (Fig. 6C). Upon histopathological evaluation,
mice receiving Huh7-lenti-shCD133 cells showed a bet-
ter histology with the reduced tumor burden and lower
size of cell populations that were expressing CSC marker
CD133 and proliferation marker Ki-67 (Fig. 6D,E).
Next, to study the molecular basis of growth inhibition
caused by CD133 loss, we compared global gene expres-
sion patterns of CD133-deficient Huh7 cells to those of
control cells with a control shRNA by using an Illumina
microarray platform. We first observed that the growth
inhibition in CD133-depeleted Huh7 cells could be
attributed, in part, to the defective cell-cycle progres-
sion. Flow cytometry (FCM) analysis revealed that
shRNA silencing of CD133 had increased G0/G1 and
decreased S-phase cell populations, suggesting a cell-
cycle arrest in G1 phase (Fig. 7A). Supporting this phe-
notypic change, CD133 silencing decreased levels of
cell-cycle regulators, such as cyclin A and D1, and
increased levels of cdk inhibitor p21 (Fig. 7B). In this
condition, a total of 1,540 genes were dysregulated (300
genes up-regulated and 1,240 down-regulated) by more
than 2-fold in 48 hours of CD133 knockdown (Fig.
7C). Of those, in particular, eight genes (TACC1,
ACF7, CKAP5, SKAP2, CLASP1, CLASP2, TRIP-Br2,
and MAP4K4) that are functionally involved in mitotic
progression, such as localization of centrosomes and reg-
ulation of microtubule dynamics at the kinetochore,28,29
were down-regulated (Fig. 7D). These results indicate
that CSC marker CD133 may be an important regula-
tor of HCC progression, and therapeutic targeting of
CD133 can be a novel therapeutic modality for HCC.
Sorafenib and STAT3 Inhibitor Nifuroxazide
Suppress CD133 Expression and Liver Tumor
Growth In Vivo. We observed that CD133 levels
were elevated in human HCC clinical specimens as well
as in a DEN-induced HCC mouse model. Whereas sor-
afenib inhibited transcriptional activity and expression
Fig. 6. CD133 silencing inhibits HCC cell proliferation in vitro and suppresses tumor formation in vivo. (A) Levels of CD133 mRNA were ana-
lyzed in Huh7 and PLC/PRF/5 cells transduced with lenti-vehicle or lenti-shCD133. (B) Lentiviral transduced Huh7 and PLC/PRF/5 cells were
incubated for the indicated time points and viable cells were counted using trypan blue staining. Data represent the mean6 standard deviation
derived from three independent experiments. (C) Lentiviral-transduced Huh7 cells were SC injected into the dorsal flank of Balb/c nude mice.
Tumor xenografts were isolated in 8 weeks of injection, and the size was measured. Maximum tumor size (diameter) was examined before sacri-
fice. **P< 0.005. (D) H&E staining and IHC analysis were performed in xenograft tissues. (E) Quantification of Ki-67 expression. Two sections
of each xenograft (5-10 fields/section) were subject to histological assessment (n5 5). **P< 0.005. Abbreviation: H&E, hematoxylin and
eosin.
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of CD133 as well as disrupted STAT3-mediated
CD133 up-regulation in either IL-6- or hypoxia-
induced HCC cells, there was a concomitant decrease in
levels of active STAT3 and HIF-1a. Therefore, we inves-
tigated whether sorafenib and STAT3 inhibitor nifurox-
azide30 could suppress liver tumor growth in vivo by
inhibiting the functional changes of tumor microenvir-
onmental factors. HCC tumor growth and population
were dramatically increased in control mice with SC
injection of Huh7 cells upon 2 weeks, whereas treatment
of either sorafenib or nifuroxazide remarkably sup-
pressed growth and population (Fig. 8A). Upon histo-
logical evaluation, elevated tumor population and levels
of active STAT3, HIF-1a, and CD133 were observed in
control mice. However, tumor growth-associated popu-
lation and factors were dramatically decreased in sorafe-
nib- and nifuroxazide-treated mice (Fig. 8B).
Coinciding with the microarray analysis in vitro (Fig.
7D), both sorafenib and nifuroxazide down-regulated
expression of TACC1, ACF7, CKAP5, SKAP2,
CLASP1, CLASP2, TRIP-Br2, and MAP4K4 genes by
suppressing CD133 expression in Huh7-derived xeno-
graft (Supporting Fig. 7). Western blotting also showed
that down-regulation of CD133 consequently decreased
levels of downstream targets, such as cyclin A, cyclin
D1, B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra
large (Bcl-xL), myeloid cell leukemia 1 (Mcl-1), and sur-
vivin, and increased cdk inhibitor p21 in tumor tissues
(Fig. 8C). Meanwhile, owing to antiangiogenic activity
of sorafenib by inhibiting levels of vascular endothelial
growth factor (VEGF) and CD31 in HCC, we further
evaluated molecular changes of these factors. Consistent
Fig. 7. CD133 silencing induces cell-cycle arrest by inhibiting expression of cytokinesis-related genes. (A) Cell-cycle profiles were evaluated
using propidium iodide staining and FCM. (B) Proteins were prepared from Huh7 cells transduced with lenti-vehicle or lenti-shCD133 and ana-
lyzed by western blotting analysis. (C) Comparison of global gene expression in between Huh7-lenti-vehicle and Huh7-lenti-shCD133 cells. Plot
locations of cytokinesis-related genes are highlighted. (D) Expression of cytokinesis-related genes was validated by quantitative real-time PCR
analysis. **P< 0.005. Abbreviation: GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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with previously reported results,25 sorafenib effectively
reduced these levels in tissues of HCC tumor xenograft
mice (Supporting Fig. 8). VEGF- and CD31-
immunoreactive cells were distributed around microves-
sels in tumor tissues of control mice, but these cells were
not observed in sorafenib-treated xenograft mice. Our
findings suggest that IL-6/STAT3 signaling promotes
expression of CD133 with a concomitant increase of
HIF-1a during liver carcinogenesis (Fig. 8D), and thus
targeting IL-6/STAT3-mediated CD133 up-regulation
may be a valuable therapy in eradication of this subset
of cells.
Discussion
Identification of signaling pathways or biomarkers
and correlation of their functions to CSC biology are
priorities for development of novel cancer therapeutic
strategies. There are accumulating evidences to show
that several hepatic stem/progenitor markers, such as
CD133, CD24, epithelial cell adhesion molecule, and
CD90, are useful for isolating a subpopulation of HCC
cells that have the preferential ability to induce self-
renewal, tumorigenicity, and chemoresistance.4-6,31,32
However, most studies have concentrated on the identi-
fication of surface markers to isolate this subset of
CSCs. Studies focused on characterizing the molecular
signaling pathways and functions of CSC marker in
tumor microenvironment are lacking. There is accumu-
lating evidences to show that CD133, a universal marker
of organ-specific stem cells and CSCs, can be used to
predict and diagnose development of various malignan-
cies, including HCC. In addition to its role as a liver
CSC marker, CD133 was also found to be functionally
important in regulating tumorigenesis of liver CSCs
through CD133 shRNA knockdown assays.32 This find-
ing now clearly suggests that CD1331 liver CSCs repre-
sent an important subpopulation of cells responsible for
driving and maintaining HCC.
Despite the significant relevance of enhanced expres-
sion of CD133 to HCC progression, fundamental
mechanisms underlying deregulation of CD133 are not
known. The improved understanding of the molecular
pathway by which CD133 is deregulated in HCC will
provide useful information for elucidation of liver CSC
origin and development of novel treatment strategies
Fig. 8. Sorafenib and nifuroxazide suppress liver tumor growth in mice by suppressing activation and expression of STAT3, HIF-1a, and
CD133. (A-C) Viable Huh7 cells were injected SC into the dorsal flank of Balb/c nude mice and tumor-bearing mice were randomly assigned to
three groups. Mice were treated with vehicle, sorafenib (30 mg/kg), or nifuroxazide (60 mg/kg) with a 2-day interval during 2 weeks. (A) Differ-
ences of tumor sizes in between vehicle- and agent-treated groups were compared using analysis of variance. Data represent the mean6 stan-
dard error of the mean (n5 6); *P< 0.05; **P< 0.005. (B) IHC analysis of active STAT3, HIF-1a, and CD133 in xenograft tissues. (C)
Reverse-transcriptase PCR or western blotting analysis of the indicated targets in xenograft tissues. b-actin and GAPDH were used as loading
controls. (D) Schematic diagram of IL-6/STAT3 signaling-mediated CD133 up-regulation responsible for HCC tumorigenesis in the hypoxic micro-
environment. Red arrows and words indicate novel mechanisms in HCC progression. Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydro-
genase; H&E, hematoxylin and eosin.
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against the deadly disease. Here, we provide data to
show that IL-6/STAT3 signaling is critical in the induc-
tion of CD133 expression through activation of HIF-1a
in a hypoxic liver tumor microenvironment. Therapeu-
tic targeting of CD133 by shRNA knockdown induced
cell-cycle arrest in HCC cells in vitro and led to retarda-
tion of xenograft-tumor progression in vivo. More
important, our findings suggest that CD133 expression
can be induced by IL-6 and hypoxic conditions in a
STAT3-dependent manner. STAT3 promotes tumori-
genesis and regulates numerous oncogenic and inflam-
matory genes.8 We have recently reported that STAT3
contributes to angiogenesis by enhancing stability of
HIF-1a protein under hypoxic conditions and induces
aggressive proliferation by regulating expression of
cyclin D1, an important cell-cycle–regulatory protein
required for G1/S-phase transition.
33
In this study, we demonstrated that IL-6 and the
hypoxic tumor microenvironment are critical for induc-
tion of CD133 expression by STAT3 activation. We
also found that STAT3 plays an important role in
switching over transcriptionally active or inactive forms
of CD133 promoter to accompany histone modifica-
tions. As demonstrated by ChIP assays, STAT3 activated
by IL-6 rapidly translocated to the nucleus and bound
to the CD133 promoter region. On the other hand,
nonhistone chromosomal proteins, such as methyl-CpG
binding protein MeCP2, HDAC1, and HDAC3, were
gradually discharged from CD133 promoter by active
STAT3. Another report in support of the epigenetic
modification of CD133 promoter is that histone
demethylase KDM5A was significantly elevated in drug-
resistant cancer cells and exhibited higher levels of
CD133 cells owing to demethylation of the CD133
promoter region.34 In endometrial cancer cells, the
regions of CD133 promoter were also hypomethylated
in malignant endometrial tissue, relative to benign con-
trol endometrial tissue.35 Taken together, these results
suggest that STAT3 induces nonmutational chromatin-
mediated modulation of the CD133 promoter, leading
to aggressive tumor progression in HCC cells.
Sorafenib, originally developed as an inhibitor of Raf
and receptor tyrosine kinase signaling, suppresses tumor
propagation and angiogenesis by inhibiting Raf/mitogen
activated protein kinase kinase/extracellular signal-
regulated kinase as well as various receptor tyrosine
kinases, such as VEGFR and platelet-derived growth
factor receptor.25 Recent studies have reported that sora-
fenib down-regulates the expressions of Bcl-xL and Mcl-
1, the transcriptional targets of STAT3, and sensitizes
cells to TRAIL-mediated apoptosis at micromolar con-
centrations.36,37 However, a multiple tyrosine kinase
inhibitor (MKI), sorafenib, causes “hand-foot skin reac-
tion” owing to a potentially dose-limiting cutaneous
toxicity in 21%-45% of advanced HCC patients. This
condition is mainly determined by dosage, peak plasma
level, total cumulative dose, and schedule of administra-
tion of MKIs.38,39 Given that subnanomolar concentra-
tions of sorafenib would be effective against STAT3/
HIF-1a activation, as demonstrated in this study,
patients with advanced HCC can be considered for
administration of low-dose sorafenib with a combined
therapy regimen.
Taken together, we report, for the first time, that IL-6
and hypoxia regulate expression of CD133 in a STAT3-
dependent manner, resulting in HCC tumorigenesis.
Our results indicate that targeting the tumor microen-
vironment can be considered as one of the therapeutic
strategies to prevent patients with liver diseases from
development of malignancies. In summary, CD133 is
an important regulator of HCC growth, survival, and
angiogenesis, and STAT3-mediated CD133 up-
regulation may represent a promising target functional
pathway for systemic therapy of a wide spectrum of
human HCC.
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